Skip to main content
    S

    Syndax Pharmaceuticals Inc (SNDX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.13
    -0.32 (-3.39%)

    Market Cap: $850.77M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Syndax Pharmaceuticals Inc (SNDX) Earnings: Report Dates and Results

    Updated Nov 2, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Syndax Pharmaceuticals (SNDX) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Syndax Pharmaceuticals reported EPS of -$0.55, below the -$0.52 estimate. It beat the EPS estimate in 4 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +11.01%

    Upcoming Estimates

    Reports Feb 24, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.50
    Range-$0.59 - -$0.28
    14 analysts
    Revenue Consensus
    $97.41M
    Range$85.26M - $134.27M
    13 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.28
    Range-$0.42 - -$0.08
    3 analysts
    EPS Revisions
    0
    1
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.07-289.3%
    60d ago-$0.07-289.3%
    30d ago-$0.07-289.3%
    7d ago-$0.08-241.8%
    Current-$0.28
    Revenue Consensus
    $95.95M
    Range$95.30M - $96.61M
    2 analysts

    Next Report

    SNDX has an expected report date of Feb 24, 2027.

    SNDX Earnings Call

    The latest SNDX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, SNDX beat 27, missed 10 and matched 3. Revenue for the quarter ended Sep 30, 2026 was $83.30M, up 81.6% from $45.87M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.55-$0.52-$0.58 - -$0.38-5.77%MissN/A110 up, 1 downNov 2, 2026$83.30M
    Jun 30, 2026-$0.55-$0.45-$0.67 - -$0.33-22.22%MissN/A11N/AAug 4, 2026$72.79M
    Mar 31, 2026-$0.48-$0.59-$0.83 - -$0.39+18.64%BeatN/A111 up, 1 downApr 30, 2026$64.86M
    Dec 31, 2025-$0.78-$0.64-$0.82 - -$0.06-21.88%MissN/A125 up, 1 downFeb 26, 2026$68.48M
    Sep 30, 2025-$0.70-$0.71-$0.97 - -$0.54+1.41%BeatN/A120 up, 2 downNov 3, 2025$45.87M
    Jun 30, 2025-$0.83-$1.01-$1.12 - -$0.85+17.82%BeatN/A111 up, 1 downAug 4, 2025$37.96M
    Mar 31, 2025-$0.98-$1.27-$4.08 - -$0.59+22.83%BeatN/A111 up, 1 downMay 5, 2025$20.04M
    Dec 31, 2024-$1.10-$0.23-$1.27 - $3.49-380.56%MissN/A131 up, 1 downMar 3, 2025$7.68M
    Sep 30, 2024-$0.98-$1.06-$1.26 - -$0.82+7.55%BeatN/A120 up, 0 downNov 5, 2024$12.50M
    Jun 30, 2024-$0.80-$0.91-$0.97 - -$0.87+12.09%BeatN/A120 up, 0 downAug 1, 2024$3.50M
    Mar 31, 2024-$0.85-$0.98-$1.11 - -$0.90+13.27%BeatN/A112 up, 0 downMay 8, 2024N/A
    Dec 31, 2023-$1.00-$0.97-$1.15 - -$0.84-3.09%MissN/A101 up, 0 downFeb 27, 2024$536000
    Sep 30, 2023-$0.73-$0.80-$0.87 - -$0.75+8.75%BeatN/A100 up, 0 downNov 2, 2023N/A
    Jun 30, 2023-$0.64-$0.75-$0.81 - -$0.61+14.67%BeatN/A90 up, 0 downAug 3, 2023N/A
    Mar 31, 2023-$0.59-$0.61-$0.65 - -$0.56+3.28%BeatN/A70 up, 0 downMay 8, 2023N/A
    Dec 31, 2022-$0.62-$0.65-$0.71 - -$0.58+4.62%Beat-134.3%80 up, 0 downFeb 28, 2023N/A
    Sep 30, 2022-$0.58-$0.63-$0.66 - -$0.60+7.94%BeatN/A60 up, 0 downNov 3, 2022N/A
    Jun 30, 2022-$0.62-$0.62N/A0.00%In lineN/AN/A0 up, 0 downAug 8, 2022N/A
    Mar 31, 2022-$0.63-$0.68-$0.68 - -$0.51+7.35%BeatN/A61 up, 0 downMay 9, 2022N/A
    Dec 31, 2021$1.81$0.28-$0.74 - $2.51+546.43%BeatN/A60 up, 0 downMar 1, 2022$126.58M
    Sep 30, 2021-$0.40-$0.57-$0.65 - $1.54+29.82%BeatN/A6N/ANov 15, 2021$12.38M
    Jun 30, 2021-$0.44-$0.73-$0.77 - -$0.64+39.73%BeatN/A6N/AAug 9, 2021$379000
    Mar 31, 2021-$0.54-$0.64-$0.71 - -$0.58+15.63%BeatN/A6N/AMay 11, 2021$379000
    Dec 31, 2020-$0.44-$0.49-$0.54 - -$0.36+10.20%BeatN/A8N/AMar 8, 2021$380000
    Sep 30, 2020-$0.46-$0.43-$0.49 - -$0.38-6.98%MissN/A5N/ANov 2, 2020$379000
    Jun 30, 2020-$0.42-$0.44-$0.53 - -$0.35+4.55%BeatN/A6N/AAug 6, 2020$379000
    Mar 31, 2020-$0.56-$0.51-$0.60 - -$0.46-9.80%MissN/A8N/AMay 7, 2020$379000
    Dec 31, 2019-$0.44-$0.43-$0.52 - -$0.32-2.33%MissN/A7N/AMar 3, 2020$380000
    Sep 30, 2019-$0.41-$0.48-$0.54 - -$0.44+14.58%BeatN/A7N/ANov 7, 2019$379000
    Jun 30, 2019-$0.47-$0.47-$0.55 - -$0.290.00%In lineN/A8N/AAug 7, 2019$379000
    Mar 31, 2019-$0.53-$0.55-$0.61 - -$0.52+3.64%BeatN/A8N/AMay 6, 2019$379000
    Dec 31, 2018-$0.70-$0.67-$0.74 - -$0.63-4.48%MissN/A8N/AMar 7, 2019$380000
    Sep 30, 2018-$0.68-$0.76-$0.94 - -$0.57+10.53%BeatN/A9N/ANov 5, 2018$379000
    Jun 30, 2018-$0.74-$0.89-$1.07 - -$0.82+16.85%BeatN/A9N/AAug 7, 2018$379000
    Mar 31, 2018-$0.79-$0.95-$1.20 - -$0.88+16.84%BeatN/A8N/AMay 8, 2018$379000
    Dec 31, 2017-$0.80-$0.78-$1.03 - -$0.61-2.56%MissN/A8N/AMar 5, 2018$1.19M
    Sep 30, 2017-$0.68-$0.82-$0.89 - -$0.74+17.07%BeatN/A8N/ANov 7, 2017$305000
    Jun 30, 2017-$0.70-$0.82-$0.91 - -$0.74+14.63%BeatN/A8N/AAug 10, 2017$305000
    Mar 31, 2017-$0.71-$0.71N/A0.00%In lineN/AN/AN/AMay 8, 2017$305000
    Dec 31, 2016-$0.59-$0.73N/A+19.18%BeatN/AN/AN/AMar 2, 2017$305000
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$3.29, after -$3.73 the year before. It was -$2.63 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$3.29N/A
    Dec 31, 2024-$3.73N/A
    Dec 31, 2023-$2.96N/A
    Dec 31, 2022-$2.45-669.8%
    Dec 31, 2021$0.43N/A
    Dec 31, 2020-$1.88N/A
    Dec 31, 2019-$1.85N/A
    Dec 31, 2018-$2.91N/A
    Dec 31, 2017-$2.89N/A
    Dec 31, 2016-$2.63N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 10,000 words across 17 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 202610,02817
    2026Q2Jun 30, 20268,04218
    2025Q4Dec 31, 20257,94818
    2025Q3Sep 30, 20257,63112
    2025Q2Jun 30, 20258,63815
    2025Q1Mar 31, 20257,67617
    2024Q4Dec 31, 20248,41419
    2024Q3Sep 30, 20248,27619

    2026Q3 Earnings Call

    Opening remarks

    Sharon Klahre Head of Investor Relations Thank you, operator. Welcome, and thank you all for joining us today for a review of Syndax's third quarter 2026 financial and operating results. I'm Sharon Klahre, and with me this afternoon to provide an update on the company's progress and discuss financial results are Michael Metzger, Chief Executive Officer; Steven Closter, Chief Commercial Officer; Dr. Nick Botwood, Head of R&D and Chief Medical Officer; and Keith Goldan, Chief Financial Officer. This call is accompanied by a slide deck that has been posted on the Investor page of the company's website. You can now turn to our forward-looking statements on Slide 2. Before we begin, I'd like to remind you that any statements made during this call that are not historical are considered to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these statements as a result of various important factors, including those discussed in the Risk Factors section in the company's most recent quarterly report on Form 10-Q, as well as other reports filed with the SEC. Any forward-looking statements made represent our views as of today, November 2nd, 2026, only. A replay of this call will be available on the company's website, www.syndax.com, following its completion. With that, I am pleased to turn the call over to Michael Metzger, Chief Executive Officer of Syndax.

    Michael Metzger CEO Thank you, Sharon, and good afternoon, everyone. Let's start on Slide 3. Syndax delivered another strong quarter of commercial growth and pipeline momentum. Total revenue reached $83 million this quarter, up 82% year-over-year. Demand for both medicines is robust, and we are moving decisively towards profitability. Revuforj net revenue grew to $61 million in the third quarter, underscoring our market leadership in both relapsed/refractory NPM1 and KMT2A acute leukemia. Similar to prior quarters, we expect Revuforj to account for the vast majority, more than 80%, of the revenue for the class this quarter, a leading position we intend to carry forward. We achieved our seventh consecutive quarter of double-digit quarter-over-quarter Revuforj net revenue growth, driven by a 20% increase in new patients and an increasing number of patients resuming Revuforj after stem cell transplant. Notably, a growing number of both KMT2A and NPM1 patients are proceeding to transplant after receiving Revuforj. As patients pause treatment to receive a transplant, this creates a short-term headwind that will become a long-term tailwind as more patients resume therapy post-transplant, extending the average duration of therapy and driving durable growth for the franchise. Every indicator of Revuforj demand is positive. The latest data are clear.

    Frequently Asked Questions About SNDX

    When is Syndax Pharmaceuticals's next earnings date?

    Syndax Pharmaceuticals's next earnings report is expected for Feb 24, 2027.

    Did SNDX beat earnings estimates last quarter?

    No. Syndax Pharmaceuticals reported EPS of -$0.55 for the quarter ended Sep 30, 2026, below the -$0.52 estimate by 5.77%.

    What EPS do analysts expect from SNDX next quarter?

    The consensus EPS estimate for Syndax Pharmaceuticals for the quarter ending Dec 31, 2026 is -$0.50 from 14 analysts, with estimates from -$0.59 to -$0.28.

    How often does SNDX beat earnings estimates?

    Syndax Pharmaceuticals beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -46.21%.